DETECTION OF JAK-2 MUTATION BY PCR TECHNIQUE IN CHRONIC MYELOPROLIFERATIVE DISORDERS | ||
| Zagazig University Medical Journal | ||
| Article 24, Volume 20, Issue 2, March 2014, Pages 1-7 PDF (614.64 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2014.4378 | ||
| Authors | ||
| Mervat Azab1; Nadia Albaz1; Foaad Abotaleb2; Abdel-Rahman Naeem1 | ||
| 1Clinical pathology departments; Zagazig university hospitals, Egypt. | ||
| 2Medical oncology departments; Zagazig university hospitals, Egypt | ||
| Abstract | ||
| At this study we aimed to detect the prevalence of JAK2 V617F mutation in various myeloproliferative neoplasms (MPNs) that represent a major advance in molecular understanding of CMPN disorders in order to identify its diagnostic value. In this study we evaluated it's clinical and laboratory correlates in 40 patients with MPNs. The mutation was detected by allele-specific PCR. The mutation was detected in 8 patients: 80% (8/10) of those with polycythemia vera, 63.6% (7/11) of those with essential thrombocythemia, 62.5% (5/8) of those with chronic idiopathic myelofibrosis and 0% (0/11) of those with chronic myeloid leukemia. The patients carrying the mutation were older (p = 0.003) and have splenomegaly in polycythemia vera group (p = 0.05) but no statistical difference was found between positive and negative JAK2 carriers as regarding HB, TLC ,PLTs count or gender type (P > 0.05). This study implies that the JAK2–V617F mutation may be useful for the diagnosis, classification and the management of patients with MPDs. | ||
| Keywords | ||
| JAK2 V617F; Polycythemia vera; Essential thrombocythemia; chronic Idiopathic myelofibrosis; Myeloproliferative neoplasms | ||
|
Statistics Article View: 261 PDF Download: 1,153 |
||
